• Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression

  NCT06351657

  RecruitingObservationalUpdated May 15, 2025
• A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression

  NCT05698316

  CompletedObservationalUpdated May 8, 2026
• An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

  NCT05300724

  Active, not recruitingObservationalUpdated Jun 17, 2026
• Functional and Anatomical Visual Investigations in Patients With Early Forms of Age-related Macular Degeneration

  NCT06694272

  RecruitingObservationalUpdated Aug 21, 2026
• Prediction of Progression of Age-Related Macular Degeneration

  NCT04640649

  Unknown statusInterventionalNot ApplicableUpdated Nov 23, 2020
• Development of Novel Clinical Endpoints in Intermediate AMD

  NCT03349801

  Active, not recruitingObservationalUpdated Jan 16, 2025

ClinicalTrials.gov ID

NCT06351670

Lead Sponsor

Medical University of ViennaOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

500Estimated

Last Update Posted

May 15, 2025Actual

Start Date

Feb 25, 2025Actual

Primary Completion Date

Jul 2027Estimated

Completion Date

Jul 2027Estimated

Official Title

Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression in a Prospective, Multinational, Multicentre Observational Study

Brief Summary

The goal of this prospective, multinational, multicenter observational study is to to predict conversion of early and intermediate AMD with functional vision to advanced AMD with irreversible loss of vision on an individual-based level over 2 years. The main objectives of this study are:

• Identify and quantify focal and global alterations in the retina in regard to disease progression.
• Assess the individual risk of disease progression in intermediate AMD patients converting to advanced AMD based on imaging.
• Specify the course of disease in regard to the sequence of events that lead to the conversion to advanced AMD
• Enhance the ability to classify AMD using artificial intelligence in addition to traditional models.

All patients will be followed for 24 months with 6 month intervals to assess clinical changes. Monitoring of disease progression will be performed using the following routine in-vivo imaging procedures:

• Scanning Laser Fundus Photography
• Color Fundus Photography (CFP)
• Optical Coherence Tomography (OCT)
• Optical Coherence Tomography Angiography (OCTA) Patients will be asked for their medical history. Standard ophthalmic examination, as well as a questionnaire on visual function will be carried out.

No intervention will be performed during the study since no treatment is yet available within Europe. As soon as treatment is approved in the EU, patients in this cohort might receive treatment according to availability in their respective country and standard of care. If treatment will be performed, it will be as standard of care outside the study according to each country's standard of care and by EMA label.

• Age-Related Macular Degeneration

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Age: 55-99 years old
• Early or intermediate AMD in at least one eye (drusen > 63 µm and/or any definite hyper- or hypopigmentary abnormalities with or without reticular pseudodrusen)
• If both eyes are eligible, both eyes will be included in the cohort study.
• Clear optical media and adequate pupillary dilation for imaging and functional testing.

Exclusion Criteria:

• Any surgical treatment of the eye within 3 months prior to baseline in the study eye
• History of anti-VEGF treatment in the study eye before baseline
• History of pseudophakic cystoid macular edema (Irvine Gass Syndrome) in the study eye
• History of uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) ≥ 25 mmHg despite treatment with IOP lowering medication), or C/D Ratio > 0.9
• Any concurrent intraocular condition in the study eye (e.g. advanced cataract or moderate/severe diabetic retinopathy) that, in the opinion of the investigator, will most likely require medical or surgical intervention during the study period to prevent or treat visual loss that might result from that condition
• Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could cause an unwanted effect on treatment efficacy, compliance or require intraocular surgery (except for cataract surgery and YAG capsulotomy) during the study period
• Presence of corneal decompensation, haze or scarring with an impact on BCVA
• Refractive error larger than 6 diopters. In case of pseudophakia or refractive surgery: History of refractive error larger than 6 diopters.
• Intake of drugs known to cause retinal toxicity (e.g. hydroxychloroquine or tamoxifen)
• Presence of active macular neovascularization at baseline

Observational Model

Case-Only

Time Perspective

Prospective

Lead Sponsor

Medical University of ViennaOTHER

Collaborators

University Medical Centre LjubljanaOTHER

Centre Hospitalier Universitaire DijonOTHER

Queen's University, BelfastOTHER

University of ZurichOTHER

Vista KlinikOTHER

Fundacion Clinic per a la Recerca BiomédicaOTHER

catherine.creuzot-garcher@chu-dijon.fr+33380293756